Abstract: Disclosed herein are treatment methods, vaccination methods, compositions, co-therapeutic methods, combination therapeutic compositions and kits comprising silvestrol and silvestrol analogs alone or in combination with therapeutic and preventative therapies. Disclosed herein are also methods, compositions and kits that can be used to treat cancer, viral infections, to modulate the immune system or as preventative therapies.

Abstract: The invention described herein relates to the treatment, detection, and diagnosis of various cancers, including esophageal or gastric adenocarcinoma and related metaplasias. The invention also includes a clonal population of Barrett's esophagus progenitor cells and methods of using them for the treatment, detection, and diagnosis of Barrett's esophagus.

Abstract: The present invention relates to compositions and methods for treating cancer. In particular, the present invention relates to EpCAM-targeted immunotoxins and uses thereof in treating peritoneal cancers expressing EpCAM (e.g., colorectal, ovarian, and pancreatic cancer).

Abstract: The invention provides a method for treating cancer using a coadministration strategy that combines local codelivery of a therapeutic agent and an intracellular penetration enhancing agent, and optionally in further combination with local administration of an immunotherapeutic agent, such as a cancer vaccine or NKT agonist. The invention also provides a method for treating cancer using an intracellular penetration enhancing agent. The methods of the invention aim to substantially kill and/or destroy the target tumor cells, as well as those cancerous cells that have metastasized to other parts of the body.

Abstract: Methods, kits, and compositions are provided for addressing cancer through the interaction of bradykinin (BK) and the bradykinin-2-receptor (B2R). This interaction controls cellular invasion, as has been unexpectedly observed in glioma cells, A composition is provided for the treatment of cancer by disrupting this interaction using an inhibitor or BK or B2R that can. be administered to the subject. Diagnostic processes are provided, involving measuring levels of BK or B2R to determine the potential for cancer (or to determine the invasive potential of a given cancer). Modulators of BK. and B2R may be used to modulate cellular migration, both in vivo and in vitro.

Abstract: P-Selectin on platelets and endothelium binds cell surface chondroitin sulfate (CS) proteoglycans, which are abundantly and stably expressed on the surface many cancer cells. Binding of the cancer cells through the CS moieties may be blocked to inhibit the interaction of cancer cells with platelets and endothelium. The present inventors disclose compositions and methods for the inhibition of cancer metastasis.

Abstract: Methods and kits for determining a risk of a subject, or subjects for developing lung cancer is disclosed. The method comprises determining a level of catalytic activity of N-methylpurine DNA glycosylase (MPG), or apurinic/apyrimidinic endonuclease 1 (APE1), or both, or MPG and 8-oxoguanine DNA glycosylase (OGG1), or MPG and APE1 and OGG1 in peripheral blood cells of a subject, wherein levels of MPG above a predetermined reference value, or APE1 or OGG1, or a integrated DNA repair score below a predetermined reference value is indicative of an increased risk of developing lung cancer.

Abstract: Provided are novel methods and compositions for the diagnosis, prognosis and treatment of gynecological tumors, in particular uterine leiomyoma (UL). Furthermore, novel methods and compositions for the treatment of diseases characterized by an aberrant growth of mesenchymal stem cells and their descendants and for the treatment of pituitary and prostate tumors are described.

Abstract: The present invention concerns methods for the treatment of diffuse large cell lymphoma by administration of an anti-CD20 antibody and chemotherapy. Particular embodiments include the administration of anti-CD20 antibody in combination with chemotherapy comprising CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) and/or in combination with a transplantation regimen.

Abstract: The present invention is based on the unexpected finding that, in addition to catalase, SOD is also involved in protecting tumor cells, wherein the inhibition effects of the two protective enzymes support one another in a complementary manner. The invention thus relates to pharmaceutical compositions containing at least two antibodies or the biologically active fragments thereof, wherein the one antibody is directed against the catalase and the other antibody is directed against the superoxide dismutase, as well as their use for treating a tumor disease.

Abstract: Methods for treating diseases such as cancer comprising administering a Wnt pathway inhibitor, either alone or in combination with other anti-cancer agents, and monitoring for skeletal-related side effects and/or toxicity.

Abstract: The invention relates to modulating the SIRP?—CD47 interaction in order to treat hematological cancer and compounds therefor. In particular, there is also provided SIRP? antibodies and antibody fragments, preferably used for treating hematological cancer.

Abstract: Provided is a method of decreasing the stability of HER2 (human epidermal growth factor receptor 2) in a cell or individual comprising administering an effective amount of an expression or activity inhibitor of KRT19 (cytokeratin 19) to the cell or individual.

Abstract: The invention is drawn to a composition comprising an isolated mixture of cytotoxic anti-CD20 antibody molecules produced in a transgenic avian. The antibody molecules have a heavy chain and a light chain whose amino acid sequences set forth in SEQ ID NOs: 4 and 5 and exhibit an increased level of cytotoxicity as compared to anti-CD20 antibody molecules produced in CHO cells.

Abstract: The invention provides Nrp2 antagonists, such as anti-Nrp2 antibodies, and their use in the prevention and treatment of tumor metastasis.

Abstract: The present invention relates to the use of a milled homogenate and/or a suspension and/or a cell lysate, stemming from a tumor resistant to at least one anti-tumoral compound in order to immunize and generate in vitro an antibody, or one of its functional fragments, directed against a tumoral antigen specifically expressed at the surface of said resistant tumor and being possibly involved in the resistance of said resistant tumor. More particularly, the present invention is directed to such antibodies obtained by applying the method, such as the antibodies 1A6, 1A9, 2E11, 3C11 and 3G7, as well as to their use for treating cancer.

Abstract: Monoclonal antibodies that specifically bind to an extracellular domain of human Jagged 1 and inhibit growth of a tumor comprising cancer stem cells are described. Also described is a method of treating cancer that comprises administering a therapeutically effective amount of a monoclonal anti-Jagged 1 antibody.

Abstract: Methods for the treatment of tumors and cancer by exploiting the surface expression of the usually nuclear-localized protein, nucleolin.

Abstract: Disclosed herein is a driver gene signature for predicting survival in patients with solid tumors, such as hepatocellular carcinoma (HCC) and breast cancer. The gene signature includes ten tumor-associated genes, SH2D4A, CCDC25, ELP3, DLC1, PROSC, SORBS3, HNRPD, PAQR3, PHF17 and DCK. A decrease in DNA copy number or mRNA expression of SH2D4A, CCDC25, ELP3, DLC1, PROSC and SORBS3 in solid tumors is associated with a poor prognosis, while a decrease in DNA copy number or mRNA expression of HNRPD, PAQR3, PHF17 and DCK in solid tumors is associated with a good prognosis. Methods of predicting the prognosis of a patient diagnosed with HCC or breast cancer by detecting expression of one of more tumor-associated genes, and methods of treating a patient diagnosed with HCC or breast cancer by administering an agent that alters expression or activity of one or more of the disclosed tumor-associated genes, are described.

Abstract: The present invention provides an antibody which recognizes an epitope recognized by an antibody produced by a hybridoma SH348-1 (FERM BP-10836) or a hybridoma SH357-1 (FERM BP-10837), an antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, an antibody obtained by humanizing the antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, a pharmaceutical agent comprising the antibody as an active ingredient, etc.

Abstract: The present invention provides nanoparticles including a metallic core having a length along each axis of from 1 to 100 nanometers and a coating disposed on at least part of the surface of the metallic core, wherein the coating comprises polydopamine, along with methods for making and using such nanoparticles. The metallic core may be gold, silver or iron oxide and the polydopamine coating may have other substances bound to it, such as silver, targeting ligands or antibodies, or other therapeutic or imaging contrast agents. The disclosed nanoparticles can be targeted to cells for treating cancer or bacterial infections, and for use in diagnostic imaging.

Abstract: The present invention relates to diagnostic imaging and in particular to the diagnostic imaging and therapy of cancer by means of compositions which specifically target the FSH Receptor expressed by tumor endothelial cells and circulating blood cells.

Abstract: The present invention relates to DDR1 binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind to an extracellular domain of DDR1 and modulate DDR1 activity. The present invention further provides methods of using agents that modulate the activity of DDR1, such as antibodies that specifically bind DDR1, to reduce the tumorigenicity of tumors comprising cancer stem cells by reducing the frequency or number of cancer stem cells in the tumor. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.

Abstract: Using phosphoproteomics, we profiled the phosphorylation levels of hundreds of proteins concurrently across an isogenic model of breast cancer metastasis. Among them is TRPV4, a calcium channel that we found to be overexpressed in invasive breast tumors compared to ductal carcinoma in situ, a pre-neoplastic lesion and normal tissues. TRPV4 was also found to be elevated mostly in invasive breast cancer cell lines and less so in non-invasive breast cancer cell lines. These data led us to hypothesize that TRPV4 confer early traits of metastatic cancer cells. Functional studies revealed that silencing of TRPV4 expression diminished breast cancer cell migration and invasion significantly but not proliferation. Silencing expression of TRPV4 in metastatic breast cancer cells also reduced the number and size of metastatic colonies in mice. This supports the notion that TRPV4 is an attractive drug target to curb metastasis.

Abstract: The invention provides methods for treating HIF-1?-overexpressing human tumors, inhibiting HIF-1?-overexpressing tumor invasion and preventing tumor metastasis, and/or promoting tumor prophylaxis, using various types of inhibitors against the Hsp90? from the tumors.

Abstract: The present invention provides: antibodies specifically reacting against hDlk-1 and having anti-tumor activity in vivo (anti-hDlk-1 antibodies, and in particular, humanized anti-hDlk-1 antibodies); fragments of the antibodies; hybridomas that produce the antibodies; a complex of the antibody or antibody fragment and an agent; a pharmaceutical composition, a tumor therapeutic agent, a tumor diagnostic agent and an agent for inducing apoptosis in tumor cells, each of which comprises the aforementioned antibody or the like; a method for treating tumor, a method for detecting tumor, a method for inducing apoptosis in tumor cells, a kit for detecting and/or diagnosing tumor and a kit for inducing apoptosis in tumor cells, each of which comprises the use of the aforementioned antibody or the like; etc.

Abstract: Nanobiopolymeric conjugates based on biodegradable, non-toxic and non-immunogenic poly (?-L-malic acid) PMLA covalently linked to molecular modules that include morpholino antisense oligonucleotides (AONa), an siRNA or an antibody specific for an oncogenic protein in a cancer cell, and an antibody specific for a transferrin receptor protein, are provided. Methods for treating a cancer in subject with nanobiopolymeric conjugates are described.

Abstract: The present invention relates to new antibodies capable of binding specifically to the human CD151 protein, especially monoclonal antibodies of murine origin, which are chimeric and humanised, and also to the amino acid and nucleic sequences coding for those antibodies. The invention also includes use of those antibodies as medicaments for the prophylactic and/or therapeutic treatment of cancers and in diagnostic methods or kits for diseases associated with overexpression of the CD151 protein. Finally, the invention includes products and/or compositions comprising such antibodies in association with antibodies and/or anti-cancer agents or conjugated with toxins and/or radioelements and their use in the prevention and/or treatment of certain cancers.

Abstract: It is intended to identify a cancer antigenic protein specifically expressed on the surface of cancer cells and to provide an antibody targeting the antigenic protein and use of the antibody as a therapeutic and/or preventive agent for cancer. The present invention provides an antibody or a fragment thereof which has immunological reactivity with a CAPRIN-1 protein, the antibody comprising a heavy chain variable region comprising amino acid sequences of SEQ ID NOs: 5, 6, and 7 and a light chain variable region comprising amino acid sequences of SEQ ID NOs: 9, 10, and 11, and a pharmaceutical composition for treatment and/or prevention of cancer, comprising this antibody or fragment as an active ingredient.

Abstract: The present invention relates to methods for the stratification of a multiple myeloma (MM) patient comprising determining whether or not B-cells, preferably malignant B-cells of said patient express BCMA protein on their surface. Also, methods for selecting an antibody-based multiple myeloma (MM) therapy is based on whether or not BCMA is expressed on the cell surface of B-cells, preferably malignant B-cells of a patient. Furthermore, antibody-based therapies for patients who have BCMA positive malignant B-cells are provided.

Abstract: We demonstrate herein that neuritin controls the homeostasis of regulatory T cells in an antigen dependent manner. Based on this discovery, we describe herein the application of neuritin as a therapeutic agent to manipulate antigen specific regulatory T cells in various disease settings is described. Thus manipulation of Treg cells and DCs through neuritin can be used to enhance immunotherapy of autoimmune diseases, cancer and infectious diseases, as well as enhance lymphocyte engraftment in settings of donor lymphocyte infusion, bone marrow transplant, as well as other types of transplants, and adoptive transfer.

Abstract: The subject matter of the present disclosure relates to an in vitro method for the screening of anti-cancer compounds based on the capacity for these compounds to interact with neurotrophin 3 (NT-3 or NT3), to the extracellular domain or TrkC receptor and/or to inhibit the dimerization of the intracellular domain of the TrkC receptor expressed in tumor cells, particularly in neuroblastoma. The disclosure also relates to a method for predicting the presence of metastatic cancer or a bad prognosis cancer, or for determining the efficiency of an anti-cancer treatment based on the measuring of the expression level of neurotrophin 3. The disclosure further comprises kits and compounds as a medicament for the treatment of neuroblastoma or cancer overexpressing neurotrophin 3 by the tumor cells.

Abstract: Pharmaceutical compositions comprising a nucleic acid, a gene delivery polymer, and at least one adjunctive chemotherapeutic drug for the treatment of mammalian cancer or hyperproliferative disorders and methods of using thereof for the treatment of mammalian cancer or hyperproliferative disorders by intratumoral, intraperitoneal or systemic injection.

Abstract: The present invention relates to the discovery that CCL3, through at least one of its receptors CCR1 and CCR5, plays a role in the pathologies associated with myeloid neoplasms. In various embodiments, the pathologies associated with myeloid neoplasms treatable by the compositions and methods of the invention described herein include, but are not limited to, at least one of osteoclast/osteoblast imbalance, inhibition of osteoblast function, bone loss, disregulation of the hematopoietic stem cell microenvironment, abnormal hematopoietic recovery, pancytopenia, anemia, thrombocytopenia, neutropenia, bicytopenia, and erythrocytopenia. Interfering with the interaction between CCL3 and its receptors, by targeting at least one of CCL3, CCR1, CCR5, diminishes the effects of pathologies associated with myeloid neoplasms.

Abstract: The present application describes extending time to disease progression or survival in a cancer patient, where the patient's cancer displays HER activation, by treating the patient with a HER dimerization inhibitor, such as pertuzumab.

Abstract: The present invention relates generally to anti-FN14 antibodies. In particular, the anti-FN14 antibodies described herein are useful for the treatment of diseases, such as a variety of cancers, associated with expression of FN14.

Abstract: As discussed in detail herein, isolated epitope peptides derived from SEMA5B bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and/or CTL inducibility of the original sequences. Further provided are polynucleotides encoding any of the aforementioned peptides as well pharmaceutical agents or compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, pharmaceutical agents or compositions of this invention find particular utility in the treatment and/or prevention of cancers and tumors, including, for example, esophageal cancer, NSCLC, RCC and SCLC.

Abstract: Uses of Apo2L/TRAIL polypeptides and death receptor agonist antibodies to disrupt tumor associated vasculature are provided. Methods of treating cancer in mammals, kits, and articles of manufacture are also provided.

Abstract: The present invention is related to the obtaining of modified antibodies by means of DNA recombinant technology from the murine monoclonal antibody P3 (MAb P3), produced by the hybridoma cell line deposited under Budapest Treaty with accession number ECACC 94113026, and from its anti-idiotype murine monoclonal antibody 1E10(MAbai 1E10), produced by the hybridoma cell line with deposit number ECACC 97112901, with the objective of achieving monoclonal antibodies which preserve the biological function of specifically binding the antigen of the original antibodies, but being at the same time less immunogenic.

Abstract: This invention relates to agents capable of reducing the activity, amount or density of complement regulatory proteins (CRPs) on target cells. The invention also provides methods of identification of such agents, methods of making, and uses thereof.

Abstract: The technology described herein relates to antibodies and/or polypeptides which bind to MIC and inhibit MIC shedding. Methods of using such antibodies and/or polypeptides for the treatment of cancer are also described herein.

Abstract: A set of markers for cancer stem cells are provided. The cells can be prospectively isolated or identified from primary tumor samples, and possess the unique properties of cancer stem cells in functional assays for tumor initiation, cancer stem cell self-renewal and differentiation. In addition, cancer stem cells can be used as a predictor for disease progression. The CSC have the phenotype of being positive for expression of CD133, and for EGFRvIII. In another embodiment of the invention, compositions are provided of a bispecific reagent that recognizes CD133 and EGFRvIII, including bispecific antibodies, which are optionally conjugated to a detectable marker, chemotherapeutic agent are radionuclide for imaging or therapy.

Abstract: Methods are provided to manipulate phagocytosis of cancer cells, including e.g. leukemias, solid tumors including carcinomas, etc.

Abstract: A first composition comprising a ligand part being able to specifically bind to a target, the target being on a diseased cell of an organism, and an epitope part having a non-self epitope, or encoding a non-self epitope, the non-self epitope not naturally being encoded by the organism, wherein the target is internalized after forming a complex with the composition and the non-self epitope is presented on the cell surface of said diseased cell of an organism after internalization.

Abstract: Methods for preparing monomeric cytotoxic drug/carrier conjugates with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low conjugate fraction (LCF) are described. Cytotoxic drug derivative/antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described. Monomeric calicheamicin derivative/anti-CD22 antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described.

Abstract: In some embodiments, the invention pertains to therapeutic compositions for treating a brain tumor. Such therapeutic compositions generally comprise: (1) a nanovector; (2) an active agent associated with the nanovector with activity against brain tumor cells; and (3) a targeting agent associated with the nanovector with recognition activity for a marker of the brain tumor cells. In some embodiments, the active agent and the targeting agent are non-covalently associated with the nanovector. Additional embodiments of the present invention pertain to methods of treating a brain tumor in a subject (e.g., a human being) by administering the aforementioned therapeutic compositions to the subject. Further embodiments of the present disclosure pertain to methods of formulating therapeutic compositions for treating a brain tumor in a subject in a personalized manner.

Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, or antigen binding portions thereof, that specifically bind to integrin ?5?1 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies or antigen binding portions thereof are also provided. The disclosure also provides methods for treating various cancers using the anti-?5?1 antibodies or antigen binding portions thereof described herein.

Abstract: The present invention features a polypeptide, such as an antibody produced by the hybridoma SAM-6 and its use in the treatment and diagnosis of neoplasms.

Abstract: The present invention relates to a new use of a known medicament. Specifically, the invention relates to methods and compositions for enhancing the therapeutic efficacy of a therapeutic agent by increasing the uptake of the therapeutic agent by target cells, and in particular relates to a pharmaceutical composition comprising a regulating agent of lipid raft/caveolae-dependent endocytic pathway and some therapeutic agents, such as anti-tumor agents. The invention also relates to a method for screening a regulating agent of lipid raft/caveolae-dependent endocytic pathway capable of enhancing the therapeutic efficacy of anti-tumor agents.

Abstract: The present invention relates to a method of treating cancer by co-administration of an effective amount of 1-(2-methoxy-ethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium bromide and an effective amount of one or more anticancer agents selected from the group consisting of carboplatin, cisplatin, paclitaxel, vinorelbine, gemcitabine, irinotecan, docetaxel, doxorubicin, dacarbazine and rituximab, or a retuximab-containing combination therapy selected from R-ICE and R-DHAP. The treatment method of the present invention is useful for the treatment for all solid tumors and lymphomas, preferably skin cancer, bladder cancer, breast cancer, uterine cancer, ovary cancer, prostate cancer, lung cancer, colon cancer, pancreas cancer, renal cancer, gastric cancer and the like. Particularly, they are expected as therapeutic agents for tumor types which show resistance against existing anticancer agents.